Kriessmann A
Department of Cardiology and Angiology, School of Medicine, University of Tübingen, Esslingen, F.R.G.
J Cardiovasc Pharmacol. 1990;16 Suppl 3:S72-4.
Intermittent claudication is the principal symptom in stage II of peripheral arterial occlusive disease. As this is a multilocular manifestation of atherosclerosis, a distinction must be drawn between treatment of the underlying disease with consideration of the individual risk factors and improvement and abolition of the intermittent claudication. Various therapeutic principles exist, and drug therapy is the subject of controversial discussion. On the basis of eight controlled, randomized studies, it was demonstrated that in comparison with placebo a statistically significant increase in the pain-free walking distance can be achieved by oral drug administration within 3-6 months. This drug therapy should be considered for those patients with intermittent claudication who cannot undergo revascularization, angioplasty, or walking training.
间歇性跛行是外周动脉闭塞性疾病II期的主要症状。由于这是动脉粥样硬化的多部位表现,必须在考虑个体风险因素治疗基础疾病与改善和消除间歇性跛行之间加以区分。存在多种治疗原则,药物治疗是有争议的讨论主题。基于八项对照随机研究表明,与安慰剂相比,口服药物在3至6个月内可使无痛行走距离在统计学上显著增加。对于那些不能接受血运重建、血管成形术或步行训练的间歇性跛行患者,应考虑这种药物治疗。